Physician profile
Armando Salcido
NPI 1467779934
$2,383.12
in general payments reported to CMS, 2019-2025
31 companies · $219 in 2025
The $219 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $578 · 2020: $388 · 2021: $279 · 2022: $253 · 2023: $365 · 2024: $302 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $885.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $435.63 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $229.86 | 2019-2023 | Veozah |
| Novo Nordisk INC | $192.81 | 2020-2024 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $191.60 | 2019-2025 | Trelegy Ellipta |
| Pfizer INC. | $150.61 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.87 | 2019-2020 | |
| Inspire Medical Systems, INC. | $119.95 | 2023-2025 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $100.52 | 2019-2025 | Eliquis |
| Abbvie INC. | $85.60 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $80.23 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $80.05 | 2019-2021 | |
| Lilly USA, LLC | $55.96 | 2023-2025 | Mounjaro, Zepbound |
| Amgen INC. | $51.24 | 2019-2023 | Otezla, Repatha |
| Abbott Laboratories | $51.08 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $44.72 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $43.76 | 2019-2020 | |
| Eisai INC. | $37.79 | 2020 | |
| Melinta Therapeutics, LLC | $35.46 | 2019 | |
| Phathom Pharmaceuticals, INC. | $31.05 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $28.52 | 2020-2021 | |
| Amarin Pharma, INC. | $28.34 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $27.04 | 2024 | Rexulti |
| Axsome Therapeutics, INC. | $23.05 | 2024 | Auvelity |
| Allergan, INC. | $21.07 | 2020 | |
| Aytu Biopharma, INC. | $20.00 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $19.10 | 2020 | |
| Inari Medical, INC. | $18.53 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Teva Pharmaceuticals USA, INC. | $17.70 | 2020 | |
| Ibsa Pharma INC. | $11.85 | 2021 | |
| Daiichi Sankyo INC. | $11.68 | 2020 | |
| Nestle Healthcare Nutrition INC. | $11.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Armando Salcido listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.